TACC3 and hepatocellular carcinoma: Through comprehensive imaging evaluation (Fig. 1c) and immunohistochemistry (IHC) validation (Fig. 1d) in our cohort of 20 HCC patients receiving ICI therapy (10 responders vs 10 nonresponders, Supplementary Fig. 1a, b), we identified marked upregulation of TACC3 protein expression in ultrasound-guided biopsy samples from immunotherapy-resistant patients.